What happened with JAGX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Jaguar Health’s main business is human gastrointestinal medicine, developed through its subsidiary Napo Pharmaceuticals. Its main commercial drug, Mytesi, treats non-infectious diarrhea in adults with HIV/AIDS who receive antiretroviral therapy. It also supplies Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and markets Gelclair in the United States, a prescription mouth gel that protects the oral lining and relieves oral mucositis pain.
Future Pak now exclusively markets Mytesi and Canalevia-CA1 in the United States, while Jaguar remains responsible for manufacturing them. Jaguar received upfront licensing payments and may earn further payments when sales milestones are reached. Its ongoing revenue depends heavily on supplying a single customer, Woodward Specialty, under the manufacturing and supply agreement—not on royalties from that customer’s sales.
Both diarrhea drugs use crofelemer, made from latex harvested from Croton lechleri trees. Jaguar relies on outside raw-material suppliers and contract manufacturers, including Alivus Life Sciences, to produce it. Napo is developing crofelemer for additional uses, including rare gastrointestinal conditions, but those uses need regulatory approval before marketing. Canalevia-CA1 has conditional FDA approval; continued marketing requires progress toward full approval and the necessary evidence of effectiveness.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Jaguar Health’s near-term results depend heavily on Future Pak’s commercialization of Mytesi and Canalevia-CA1, the associated payments and Jaguar’s continued manufacturing supply.
Ironwood Pharmaceuticals is pursuing the same patients as Jaguar’s crofelemer powder program: people with short bowel syndrome and intestinal failure. Its development of apraglutide is the competing treatment effort to watch.
Takeda’s GATTEX already serves the short bowel syndrome treatment market Jaguar is targeting with its crofelemer intestinal-failure program, treating U.S. adults and children who depend on intravenous nutritional support. Watch GATTEX alongside Jaguar’s proposed role for crofelemer in patients who cannot use, tolerate or benefit from GLP-2 treatments such as GATTEX.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda’s report will show demand for GATTEX among people with short bowel syndrome, giving Jaguar Health a read on the market for its crofelemer intestinal-failure program in patients who cannot use or benefit from GLP-2 treatment.
Look for Takeda’s disclosure of GATTEX sales or use and any change in its short-bowel-syndrome business. Stronger demand would show that patients dependent on intravenous nutrition continue to need treatment, providing market context for Jaguar Health’s crofelemer program for people who cannot use or benefit from GLP-2 therapies; weaker demand would make Takeda’s report less supportive evidence for that opportunity.
Jaguar Health, Inc. earningsThis company
Jaguar Health still manufactures Mytesi and Canalevia-CA1 for Future Pak, and this report will show whether those products are bringing in revenue to support Jaguar’s business.
Read Mytesi and Canalevia-CA1 product sales alongside revenue from Jaguar’s human- and animal-health businesses. Steady sales and related revenue would show that patient demand is still reaching Jaguar as product income under the Future Pak arrangement; declines would show that commercialization under the new arrangement is not yet producing enough revenue to ease Jaguar’s reliance on a narrow product base and outside financing.
